Abiomed (NASDAQ: ABMD) reported Q1 EPS of $0.20, $0.12 better than the analyst estimate of $0.08. Revenue for the quarter came in at $73.4 million versus the consensus estimate of $66.27 million.

Abiomed sees FY2015 revenue of $300-310 million, versus prior guidance of $285-295 million and the consensus of $292.4 million.

For earnings history and earnings-related data on Abiomed (ABMD) click here.